Vistagen Therapeutics Stock (NASDAQ: VTGN)

Vistagen Therapeutics

VistaGen Therapeutics

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Biotech

Earnings

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

VTGN

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy

Analyst Color

Equities

Health Care

Price Target

Initiation

Movers

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other 

Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment

Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD).

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics Inc

Press Releases

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Biomea Fusion

Cabaletta Bio

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

CervoMed

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

HilleVax

IGM Biosciences

I-MAB

IO Biotech

Invivyd

Kyverna Therapeutics, Inc. - Common Stock

Comments

Vistagen Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga